Supernus Pharmaceuticals, Inc. (SUPN) — Fair Value Analysis

Base-case fair value (P50): $52.83 · Current price: $48.27 · Verdict: Fairly Valued

The Verdict on SUPN

Our Monte Carlo simulations indicate that SUPERNUS PHARMACEUTICALS INC (SUPN) is currently Fairly Valued. With the stock trading at $48.27, our median fair value estimate (P50) stands at $52.83. This suggests a potential +9.4% upside from its current trading level, placing it squarely within a reasonable valuation range. While a modest upside exists, the valuation framework suggests SUPN is not significantly over or undervalued at this juncture based on our probabilistic modeling. Investors should consider this balanced assessment when evaluating SUPN against their portfolio objectives.

How SUPN stacks up against peers

SUPN's operational and financial health is categorized as average when benchmarked against its sector peers. This assessment considers various fundamental metrics, although specific comparisons are beyond the scope here. The current price of $48.27 relative to our P50 fair value of $52.83 aligns with a company exhibiting an average quality tier. While there is a +9.4% gap, it's not substantial enough to shift the overall verdict from "Fairly Valued." An average quality rating suggests that SUPN demonstrates a stable, albeit not exceptional, financial footing within its competitive landscape.

What this means for investors

For investors, SUPN's Fairly Valued status, coupled with an average quality tier, implies a balanced risk-reward profile at $48.27. The P50 fair value of $52.83 provides a central estimate, with Monte Carlo simulations also outlining potential downside scenarios and bull-case outcomes without specific figures. The +9.4% from the current price to the median fair value suggests that current market pricing largely reflects the underlying fundamentals, warranting a closer look at individual risk tolerance and investment horizons. To fully understand the probabilistic range of outcomes, including detailed bear and bull case price targets, consider signing up for FairCurve to see the full bear/bull distribution and track SUPN's fair value as new fundamentals are released.